Author

Raluca Maria Fostea

Observed name: Raluca Fostea

Institution: Sarah Cannon Research Institute

Observed institution: Sarah Cannon Research Institute

ORCID: 0000-0002-2630-135X

Observed ORCID: 0000-0002-2630-135X

OpenAlex ID: A5088105993

Recent Progress in the Systemic Treatment of Advanced/Metastatic Cholangiocarcinoma

2020 · Raluca Maria Fostea, Elisa Fontana, et al. · Cancers · 38

Trifluridine/Tipiracil in the Treatment of Gastric Cancer

2022 · Raluca Maria Fostea, Hendrik-Tobias Arkenau · Future Oncology · 11

Sustained Tumor Regression With Zenocutuzumab, a Bispecific Antibody Targeting Human Epidermal Growth Factor Receptor 2/Human Epidermal Growth Factor Receptor 3 Signaling, in NRG1 Fusion–Positive, Estrogen Receptor–Positive Breast Cancer After Progression on a Cyclin-Dependent Kinase 4/6 Inhibitor

2022 · Elisa Fontana, Gonzalo Torga, et al. · JCO Precision Oncology · 8

Abstract GS3-10: Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)

2022 · Charles Coombes, Sasha J Howell, et al. · Cancer Research · 7

Works count: 4

Citation count: 64

H-index: 4

I10-index: 2